## Diagnosis: Recurrent/Relapse Tuberculosis The clinical presentation—history of prior TB, caseating granulomas on biopsy, and AFB on Ziehl-Neelsen stain—confirms **recurrent tuberculosis**. The negative sputum smear does NOT exclude active TB; it reflects the **paucibacillary nature** of the disease in this case. ## Management of Bacteriologically Confirmed TB **Key Point:** Once TB is **histologically and bacteriologically confirmed** (AFB+ on biopsy), anti-tuberculous therapy (ATT) should be initiated **without delay**, even if sputum smear is negative. Sputum culture and drug-susceptibility testing (DST) are sent **simultaneously** to guide therapy optimization, but treatment must not be withheld pending results. ### Rationale for Immediate Therapy | Factor | Implication | | --- | --- | | **Biopsy AFB+** | Confirms active mycobacterial infection | | **Caseating granulomas** | Pathognomonic for TB | | **Sputum smear negative** | Does NOT exclude TB; ~30% of culture-positive TB are smear-negative | | **Delay in therapy** | Risks progressive lung damage, dissemination, and mortality | **High-Yield:** WHO and Indian TB guidelines mandate **immediate initiation of ATT** in bacteriologically confirmed TB, regardless of smear status. Culture and DST are sent to: 1. Confirm species (rule out NTM) 2. Detect drug resistance (MDR-TB, XDR-TB) 3. Guide therapy modification if resistance detected **Clinical Pearl:** In this case, the patient has **biopsy-confirmed TB with AFB positivity**—this is **bacteriological confirmation**. Sputum smear negativity does not delay therapy; it only reflects lower bacillary load, not absence of disease. ### Standard Regimen for Recurrent TB - **Intensive phase (2 months):** Isoniazid (INH) + Rifampicin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB) - **Continuation phase (4 months):** INH + RIF - **Total duration:** 6 months (assuming drug-susceptible TB) ## Why Other Options Are Incorrect ```mermaid flowchart TD A[TB Suspected]:::outcome --> B{Bacteriological Confirmation?}:::decision B -->|Sputum smear+| C[Initiate ATT immediately]:::action B -->|Sputum smear−| D{Biopsy AFB+ or Culture+?}:::decision D -->|Yes| C D -->|No| E[Further investigation]:::action C --> F[Send sputum for culture & DST]:::action F --> G{Resistance detected?}:::decision G -->|Yes| H[Modify regimen]:::action G -->|No| I[Continue standard regimen]:::action ``` - **Repeat sputum induction/BAL before therapy:** Unnecessary delay. Biopsy AFB+ is sufficient confirmation. Sputum smear negativity does not negate the need for immediate treatment. - **Immediate DOT without culture/DST:** While DOT is correct, awaiting culture/DST results is not a prerequisite for starting therapy; both should proceed in parallel. - **CT-guided lung biopsy:** Redundant. Diagnosis is already confirmed by transbronchial biopsy with AFB; additional biopsy delays critical therapy. [cite:Harrison 21e Ch 205; RNTCP Guidelines 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.